Add to Calendar 8/26/2020 8:00:00 AM 8/27/2020 5:00:00 PM 2020 State of Possible Conference

Special thanks to our Platinum Sponsor Morgan Stanley

Registered attendees will receive an email with the subject line “Welcome to the State of Possible Conference 2020 - Event Access Link” from

The State of Possible Conference, MassBio's Annual Meeting, will now be hosted virtually on August 26-27, 2020. Featuring interactive networking and a groundbreaking viewer experience, this event will not be your average webinar.  

We will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks®, inspiring and engaging content in the style of a TED Talk.

"It's the Woodstock of Life Sciences, with all-star performers playing their greatest hits all on one stage.” – 2019 State of Possible Conference attendee
If you haven’t attended our State of Possible Conference before, it is the premier east coast life sciences conference. We have some of the brightest names in biotech talking about the issues impacting our industry, covering topics from the realities of precision medicine to advancing new drug targets faster.

To inquire about sponsorship opportunities, contact Laura Rudberg.

2020 State of Possible Conference Refund Policy

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
Online Conference, Link will be sent in advance of the event.
VP, Neurodegeneration & Repair, Biogen
After training at the University of Cambridge (UK) and spending much of his career in France, Chris Henderson moved in 2005 to Columbia University in New York, where he co-founded the Center for Motor Neuron Biology and Disease, an initiative in translational neuroscience that created a continuum from research on motor neurons through to clinical research on the motor neuron diseases ALS (amyotrophic lateral sclerosis) and SMA (spinal muscular atrophy). He was also director of the Columbia Stem Cell Initiative, a group of 120 laboratories across the university using stem cells to better understand or treat human disease. While still at Columbia, he became (and remains) director of Target ALS, a privately-funded foundation that has stimulated industry investment in ALS research by supporting cutting-edge translational research and nationwide core facilities. In 2014, Trophos - a French biotech of which he was an academic founder - announced positive clinical trial data in patients with SMA and was acquired by Roche. This provided major motivation to become more actively engaged in the biotech world and in October 2014, Henderson moved to Biogen (Cambridge, MA) to lead the neuroscience research program. As Vice President of Neurodegeneration & Repair, he works with a team of clinicians and scientists to take programs on Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, ataxias, ALS, SMA and multiple sclerosis from early research to clinical proof of concept.

Brought to you by